

#4
1631

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of : Emil Israel KATZ
Serial No. : 09/982,172
Filed : October 19, 2001
For: : PEPTIDES REPRESENTATIVE OF
POLYPEPTIDES OF INTEREST ...
Attorney Docket : 01/22283
Art Unit :

MAR 04 2002

TECH CENTER 1600/2900



Commissioner of Patents and Trademarks
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.


Respectfully submitted,

Sol Sheinbein
Attorney for Applicant
Registration No. 25,457

February 26, 2002

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/982,172
			Filing Date	October 19, 200
			First Named Inventor	KATZ et al
			Group Art Unit	
			Examiner Name	
Sheet	2	of	Attorney Docket Number	01/22283
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	BA	Marks et al, "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", <i>Bio/technology</i> , 10:779-783, 1992		
	BB	Söderlind et al, "Complementary-Determining Region (CDR) Implantation: A Theme of Recombination", <i>Immunotechnology</i> , 4:279-285, 1999		
	BC	Söderlind et al, "Recombining Germline-Derived CDR Sequences for Creating Diverse Single-Framework Antibody Libraries", <i>Nature Biotechnology</i> , 18:852-856, 2000		
	BD	Ohlin et al, Light Chain Shuffling of a High Affinity Antibody Results in a Drift in Epitope Recognition", <i>Molecular Immunology</i> , 33(1):47-56, 1996		
	BE	Hemminki et al, "Fine Tuning of an Anti-Testosterone Antibody Binding Site by Stepwise Optimisation of the CDRs", <i>Immunotechnology</i> , 4:59-69, 1998		
	BF	Barbas III et al, "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site", <i>Proc. Natl. Acad. Sci. USA</i> , 88:7978-7982, 1991		
	BG	Hoogenboom et al, "Antibody Phage Display Technology and its Applications", <i>Molecular Immunology</i> , 4:1-20, 1998		
	BH	Haupt et al, "Plastic Antibodies: Developments and Applications", <i>Trends Biotech.</i> , 16:468-476, 1998		
	BI	Vlatakis et al, "Drug Assay Using Antibody Mimics Made by Molecular Imprinting", <i>Nature</i> , 361:645647, 1993		
	BJ	Arnon, R., "Synthetic Peptides as the Basis for Vaccine Design", <i>Molecular Immunology</i> , no further info given		
	BK	Arnheiter et al, "Physicochemical and Antigenic Properties of Synthetic Fragments of Human Leukocyte Interferon" <i>Nature</i> , 294:278-280, 1981		
	BL	Mariani et al, "Immunogenicity of a Free Synthetic Peptide: Carrier Conjugation Enhances Antibody Affinity for the Native Protein", <i>Molecular Immunology</i> , 24(3):297-303, 1987		
	BM	Chames et al, "Antibody Engineering and its Applications in Tumor Targeting and Intracellular Immunization", <i>FEMS Microbiology Letters</i> , 189:1-8, 2000		
	BN	Hoogenboom et al, "Natural and Designer Binding Sites Made by Phage Display Technology", <i>Immunology Today</i> , 21(8):371-378, 2000		
	BO	Nelson et al, "Demystified... Monoclonal Antibodies", <i>J. Clin. Pathol.: Mol Pathol.</i> , 53:111-117, 2000		
	BP	Li, Min, "Applications of Display Technology in Protein Analysis", <i>Nature Biotechnology</i> , 18:1251-1256, 2000		
	BQ	Borrebaeck, Carl A.K., "Antibodies in Diagnostics-From Immunoassays to Protein Chips", <i>Immunology Today</i> , 21(8):379-381, 2000		
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 2023 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.